Cytori Announced Resluts Of Bioequivalence Trial Of ATI-0918 And European Sourced CAELYX, Says Pharmacokinetic Bioequivalence Shown for Cytori's ATI-0918 Liposomal Formulation of Doxorubicin Hydrochloride